Patient Received Permission to Be Treated with RSHO-X™ for Pain Associated with Cancer Treatment and General Well-Being
SAN DIEGO, Jan. 24, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) announced today that its subsidiary HempMeds Mexico® has received permission from Mexico’s health authority COFEPRIS to import their flagship product Real Scientific Hemp Oil-X™ (RSHO-X™) to treat a patient for their pain associated with cancer treatments and for their general well-being.
The patient, a 44-year-old woman suffering from Stage 5 breast cancer, has received the COFEPRIS permission in order to treat pain she has experienced as a result of Chemotherapy. This approval comes nearly one year after HempMeds Mexico® received the first-ever permit from the federal government of Mexico to import a cannabis product from the U.S. into Mexico, after developing the zero-THC hemp cannabidiol (CBD) product RSHO-X™ to meet specific requirements laid out by Mexico’s health authority.
“We applaud and wholeheartedly stand by the decision made by COFEPRIS to approve this import permit for this consumer in Mexico,” said Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. “The decision made by Mexico to allow our subsidiary’s product to be imported represents progressive thinking toward the resolution of rehabilitation problems experienced by post-chemotherapy patients. In the U.S., we see many progressive doctors prescribe medical cannabis for consumers suffering post chemotherapy challenges involving; pain, nausea, vomiting, sleep disturbances, loss of appetite and depression. We believe the potential restorative and rejuvenative benefits of CBD will soon be proven by medical science – but consumers and their anecdotal evidence points toward these benefits. Mexico’s government and regulatory authorities are starting to recognize some of the potential benefits of cannabis/cannabinoid based therapeutics for the overall health and wellness of its people.”
To learn more about HempMeds Mexico®, follow the link HERE.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company, handling sales and distribution.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.